Methylprednisolone does not inhibit the release of growth hormone after intravenous injection of a novel growth hormone secretagogue in rats

Growth Hormone and IGF Research

Volumn 9, Issue 6, 1999, Pages 445-450

  Malmlof K ^a   Johansen, P B ^a   Haahr, P M ^a   Wilken, M ^a   Oxlund, H ^b  

^a NOVO NORDISK A S   (Denmark)

^b Depts Assay and Cell Technology ^*

Author keywords

GH; Glucocorticoids; Growth hormone; Growth hormone secretagogue; Ipamorelin; Methylprednisolone

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; IPAMORELIN; METHYLPREDNISOLONE; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; GROWTH INHIBITION; HORMONE BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; RAT; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 0033374781     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1054/ghir.1999.0128     Document Type: Article

References (38)

1. Blodgett F. M., Burgin L., Iezzoni D., Gribetz D., Talbot N. B. Effects of prolonged cortisone treatment on the statural growth, skeletal maturation and metabolic status of children. N Engl J Med. 254:1956;636-640.
2. Loeb J. N. Corticosteroids and growth. N Engl J Med. 295:1976;547-552.
3. King A. P. J., Carter Su C. Dexamethasone-induced antagonism of growth hormone (GH) action by down-regulation of GH binding in 3T3-F442A Fibroblasts. Endocrinology. 136:1995;4796-4803.
4. King A. P. J., Tseng M-J., Logsdon C. D., Billestrup N., Carter-Su C. Distinct cytoplasmic domains of the growth hormone receptor are required for glucocorticoid-and phorbol ester-induced decreases in growth hormone (GH) binding. J Biol Chem. 271:1996;18088-18094.
5. McGrath J. A., Goldspink D. F. Glucocorticoid action on protein synthesis and protein breakdown in isolated skeletal muscles. Biochem J. 206:1982;641-645.
6. Baron J., Huang Z., Orter K. E., Bacher J. D. Jr, Cutler J. B. Dexamethasone acts locally to inhibit longitudinal bone growth in rabbits. Am J Physiol. 263:1992;E489-E492.
7. Ørtoft G., Grønbæk H., Oxlund H. Growth hormone administration can improve growth in glucocorticoid-injected rats without affecting the lymphocytopenic effect of the glucocorticoid. Growth Hormone IGF Res. 8:1998;251-264.
8. Nogami H., Inoue K., Kawamura K. Involvement of glucocorticoid-induced factor(s) in the stimulation of growth hormone expression in the fetal rat pituitary gland in vitro. Endocrinology. 138:1997;1810-1815.
9. Martul P., Pineda J., Dieguez C., Casanueva F. F. Corticoid-induced growth hormone (GH) secretion in GH-deficient and normal children. J Clin Endocrinol Metab. 75:1992;536-539.
10. Wehrenberg W. B., Janovski B. A., Piering A. W., Culler F., Jones K. L. Glucocorticoids: potent inhibitors and stimulators of growth hormone secretion. Endocrinology. 126:1990;3200-3203.
11. Giustina A., Wehrenberg W. B. The role of glucocorticoids in the regulation of growth hormone secretion. Mechanisms and clinical significance. Trends Endocrinol Metab. 3:1992;306-311.
12. Borges M. H., DiNinno F. B., Lengyel A. M. Different effects of growth hormone releasing peptide (GHRP-6) and GH-releasing hormone on GH release in endogenous and exogenous hypercortisolism. Clin Endocrinol. 46:1997;713-718.
13. Wehrenberg W. B., Bergman P. J., Stagg L., Ndon J., Guistina A. Glucocorticoid inhibition of growth in rats: partial reversal with somatostatin antibodies. Endocrinology. 127:1990;2705-2708.
14. Fife S. K., Brogan R. S., Giustina A., Wehrenberg W. B. Immunocytochemical and molecular analysis of the effects of glucocorticoid treatment on the hypothalamic-somatotropic axis in the rat. Neuroendocrinol. 64:1996;131-138.
15. Horber F. F., Haymond M. W. Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest. 86:1990;265-272.
16. Kovacs G., Fine R. N., Worgall S., Schaefer F., Hunzuiker E. B., Skottner-Lundin A., Mehls O. Growth hormone prevents steroid-induced growth depression in health and uremia. Kidney Int. 40:1991;1032-1040.
17. Giustina A., Buffoli M. G., Bussi A. R., Doga M., Girelli A., Pizzocolo G., Pozzi A., Wehrenberg W. B. Comparative effect of clonidine and growth hormone (GH)-releasing hormone on GH secretion in adult patients on chronic glucocorticoid therapy. Horm Metab Res. 24:1992;240-243.
18. Gertz B. J., Sciberras D. G., Yogendran L., Christie K., Bador K., Krupa D., Wittreich J. M., James I. L-692, 429, a nonpeptide growth hormone (GH) secretagogue, reverses glucocorticoid suppression of GH secretion. J Clin Endocrinol Metab. 79:1994;745-749.
19. Voltz D. M., Piering A. W., Magestro M., Guistina A., Wehrenberg W. B. Effect of GHRP-6 and GHRH on GH secretion in rats following chronic glucocorticoid treatment. Life Sci. 56:1995;491-497.
20. Raun K., Sehested Hansen B., Langeland Johansen N., Thørgersen H., Madsen K., Ankersen M., Høngaard Andersen P. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 139:1998;552-561.
21. Johansen P. B., Nowak J., Skjærbæk C., Flyvbjerg A., Andreassen T., Wilken M., Ørskov H. Ipamorelin, a new growth hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone IGF Res. 9:1999;106-113.
22. Horber F. F., Scheidegger J. R., Gruenig B. E., Frey F. J. Thigh muscle mass and function in patients treated with glucocorticoids. Eur J Clin Invest. 15:1985;302-307.
23. Sapir D. G., Pozefsky T., Knochel J. P., Walser M. The role of alanine and glutamine in steroid-induced nitrogen wasting in man. Clin Sci Mol Med. 53:1977;215-220.
24. Simmons P. S., Miles J. E., Gerich J. E., Haymond M. W. Increased proteolysis: an effect of increases in plasma cortisol within the physiological range. J Clin Invest. 73:1984;412-420.
25. Johansen T., Deckert M., Mandrup-Poulsen T., Malmlöf K. The role of growth hormone and glucocorticoid in glucose handling in vivo. J Endocrinol. 162:1999;87-93.
26. Rupprecht R., Niehaus A., Lesch K-P. The influence of dexamethasone on growth hormone (GH) response to GH-releasing hormone in normal men. J Neural Transm. 79:1990;51-57.
27. Casanueva F. F., Burugera B., Tome M. A., Lima L., Tresguerres J. A., Devesa J., Dieguez C. Depending on the time of administration, dexamethasone potentiates or blocks growth hormone releasing hormone-induced growth hormone release in man. Neuroendocrinology. 47:1988;46-49.
28. Giustina A., Bussi A. R., Deghenghi R., Imbimbo B., Licini M., Poiesi C., Wehrenberg W. B. Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess. J Endocrinol. 146:1995;227-232.
29. Luo J. M., Murphy L. J. Dexamethasone inhibits growth hormone induction of insulin-like growth factor-I (IGF-I) messenger ribonucleic acid (mRNA) in hypophysectomised rats and reduces IGF-I mRNA abundance in the intact rat. Endocrinology. 125:1989;165-171.
30. Gabrielsson B. G., Carmignac D. F., Flavell D. M., Robinson I. C. Steroid regulation of growth hormone (GH) receptor and GH-binding protein messenger ribonucleic acids in the rat. Endocrinology. 136:1995;209-217.
31. Ørtoft G., Kelly C., Brüel A-M., Smith A., Carter N., Oxlund H. Glucocorticoids inhibit the growth hormone induced increase in serum IGF-I and its mRNA, body weight and muscle mass of rats. Eur J Exp Musculoskel Res. 2:1993;135-142.
32. Kaufmann S., Jones K. L., Wehrenberg W. B., Culler F. L. Inhibition by prednisone of growth hormone (GH) response to GH-releasing hormone in normal men. J Clin Endocrinol Metab. 67:1988;1258-1261.
33. Lou J., Ried R. E., Murphy L. J. Dexamethasone increases hepatic insulin-like growth factor-binding protein-1 (IGFBP-1) mRNA and serum IGFBP-1 concentrations in the rat. Endocrinology. 127:1990;1456-1462.
34. Oehri M., Ninnis R., Girard J., Frey F. J., Keller U. Effects of growth hormone and IGF-I on glucocorticoid-induced protein catabolism in humans. Am J Physiol. 270:1996;E552-E558.
35. Malmlöf K., Arrhenius-Nyberg V., Saxerholt H. The role of insulin like growth factor-I and growth hormone in counteracting dexamethasone induced nitrogen wasting in rats. Horm Metab Res. 29:1977;20-23.
36. Grøfte T., Skjærbæk C., Malmlöf K., Johansen P. B., Haahr P. M., Ørskov H., Vilstrup H. Growth hormone secretagogue ipamorelin reduces the hepatic catabolic stress response during steroid treatment. Abstract, Third International Conference of the Growth Hormone Research Society, San Francisco, USA. Growth Hormone IGF Res. 8:1998;312.
37. Andersen N. B., Oxlund H., Malmlöf K., Andreassen T. T. Growth hormone counteracts the decrease in skeletal muscle mass and contraction force induced by glucocorticoids. Abstract, 80th Annual Meeting of the Endocrine Society. 1998;P1-P101.
38. Huhn W. C., Hartman M. L., Pezzoli S. S., Thorner M. O. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus. J Endocrinol Metab. 76:1993;1202-1208.